Biotech deal activity accelerated this week with several drug developers completing high‑profile public offerings to fund clinical programs. Eikon Therapeutics priced an upsized IPO that will supply hundreds of millions for oncology and other candidates, while Agomab and SpyGlass executed Nasdaq listings raising a combined $350 million. Eikon plans to deploy proceeds to advance multiple clinical-stage programs, including a TLR7/8 co-agonist in Phase II/III and selective PARP inhibitors. Agomab and SpyGlass aim to support their immunology and ocular drug pipelines, respectively, and to expand R&D and clinical operations following their market debuts. Market participants view the string of offerings as an early sign of appetite returning to biotech equity markets after a slow period; analysts will watch aftermarket performance and whether IPO capital translates into accelerated development timelines.